Major Events - Different Group (06090) is set to launch its IPO from September 15 to September 18, with an expected listing date of September 23 [1] - Hesai Technology-W (02525) has received 168.65 times subscription for its public offering in Hong Kong, with a share price of HKD 212.80 [1] - Basilea Pharmaceutica-B (02616) will showcase CS2015 (OX40L/TSLP bispecific antibody) at ACAA 2025 [1] - CSPC Pharmaceutical Group (01093) has received clinical trial approval in China for ALMB-0166 to treat Parkinson's disease [1] - Kingdee International (00268) plans to acquire a 62.764% stake in Yunzhijia for HKD 68.25 million [1] - Lion Group Holdings (02562) intends to acquire a company leading in AI, blockchain, decentralized finance, and stablecoin innovation [1] - COSCO Shipping Holdings (01919) plans to invest CNY 370 million to establish a joint venture [1] - Shoujia Technology (00103) aims to set up a joint venture for a super new materials company [1] - CITIC Limited (00267) has its "data-driven high-end mining equipment intelligent factory" recognized as a 2025 excellent-level intelligent factory by the Ministry of Industry and Information Technology [1] - Eden Software (01147) has its self-developed "Easy AI multimodal content generation" algorithm approved for algorithm filing in Shenzhen [1] Operating Performance - Hong Kong Dragon Land (06968) reported a contract sales amount of approximately CNY 3.602 billion for the first eight months, a year-on-year decrease of 0.16% [1] - China Southern Airlines (01055) saw an 8-month passenger turnover increase of 5.97% year-on-year [1] - China Eastern Airlines (00670) reported an 8-month passenger turnover increase of 8.72% year-on-year [1] - Air China (00753) recorded a 2.3% year-on-year increase in passenger capacity input and a 3.2% increase in passenger turnover for August [1] - Hong Kong Technology Exploration (01137) reported an August total merchandise transaction value of HKD 678 million in its e-commerce business, a year-on-year decline of 4.5% [1]

基石药业-B(02616)涨超4%，截至发稿，涨4.3%，报10.43港元，成交额1.09亿港元。 国投证券此前指出，公司早期管线中，ADC产品管线CS5007(EGFR/HER3双特异性ADC)、 CS5008(DLL3/SSTR2双特异性ADC)、CS5005(SSTR2ADC)、CS5006(ITGB4ADC)以及 CS5009(B7H3/PD-L1双特异性ADC)等，以及自免管线中CS2013(BAFF/APRIL双特异性抗体)、 CS2015(OX40L/TSLP双特异性抗体)等均为具备较高潜力的差异化品种，后续的临床推进值得关注。 消息面上，基石药业今早宣布，公司自身免疫与炎症领域管线之一CS2015(OX40L/TSLP双特异性抗体) 入选2025年美国过敏，哮喘和免疫学会(ACAAI)年度科学会议，并将以"电子壁报演示+现场口头汇 报"的形式展出。本次大会将于11月6日至10日在美国奥兰多举行。据悉，CS2015是一款同时靶向 OX40L和TSLP的潜在同类首创/同类最佳双特异性抗体，通过双重抑制Th2介导炎症反应的关键调控因 子，为特应性皮炎(AD)、哮喘、慢性阻塞性肺病(COPD)等2型炎 ...

根据披露，CS2015是一款同时靶向OX40L和TSLP的潜在同类首创/同类最佳双特异性抗体，通过双重抑 制Th2介导炎症反应的关键调控因子，为特应性皮炎(AD)、哮喘、慢性阻塞性肺病(COPD)等2型炎症性 疾病提供新治疗策略。 格隆汇9月15日丨基石药业-B(02616.HK)宣布公司自身免疫与炎症领域管线之一CS2015(OX40L/TSLP双 特异性抗体)入选2025年美国过敏，哮喘和免疫学会(ACAAI)年度科学会议，并将以"电子壁报演示+现 场口头汇报"的形式展出。本次大会将于11月6日至10日在美国奥兰多举行。 ...

CS2015是一款同时靶向OX40L和TSLP的潜在同类首创/同类最佳双特异性抗体，通过双重抑制Th2介导 炎症反应的关键调控因子，为特应性皮炎(AD)、哮喘、慢性阻塞性肺病(COPD)等2型炎症性疾病提供新 治疗策略。 基石药业-B(02616)发布公告，公司自身免疫与炎症领域管线之一CS2015(OX40L/TSLP双特异性抗体)入 选2025年美国过敏，哮喘和免疫学会(ACAAI)年度科学会议，并将以"电子壁报演示+现场口头汇报"的 形式展出。本次大会将于11月6日至10日在美国奥兰多举行。 ...

CS2015是一款同时靶向OX40L和TSLP的潜在同类首创/同类最佳双特异性抗体，通过双重抑制 Th2介导 炎症反应的关键调控因子，为特应性皮炎(AD)、哮喘、慢性阻塞性肺病(COPD)等2型炎症性疾病提供新 治疗策略。 智通财经APP讯，基石药业-B(02616)发布公告，公司自身免疫与炎症领域管线之一 CS2015(OX40L/TSLP双特异性抗体)入选2025年美国过敏，哮喘和免疫学会(ACAAI)年度科学会议，并 将以"电子壁报演示+现场口头汇报"的形式展出。本次大会将于11月6日至10日在美国奥兰多举行。 ...